logo.jpg
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease
13 mai 2024 06h00 HE | AC Immune SA
AC Immune and Takeda Sign Exclusive Option and License Agreement for Active Immunotherapy Targeting Amyloid Beta for Alzheimer’s Disease Takeda to receive exclusive option to license global rights...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Announces Enrollment of Cerebral Amyloid Angiopathy Participants in Phase 1/2a Retinal Tracer Trial
21 févr. 2023 05h00 HE | Amydis, Inc.
SAN DIEGO, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Amydis Inc., a privately held clinical-stage company pioneering a platform of ocular tracers that enable imaging of disease biomarkers in the eye, today...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Receives NIH Grant Award to Develop a Novel Tau Retinal Tracer for Alzheimer's Diseases and other Tauopathies
02 sept. 2021 07h00 HE | Amydis, Inc.
SAN DIEGO, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Receives $3 Million NIH Commercialization Readiness Pilot Grant Award for Novel Amyloid Beta Retinal Tracer in Cerebral Amyloid Angiopathy
28 juin 2021 07h00 HE | Amydis, Inc.
SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Announces Successful Completion of Pre-IND Meeting with the FDA for the Development of AMDX-2011P, a First-in-Class Retinal Tracer for the Diagnosis of Amyloid Angiopathy
11 janv. 2021 07h00 HE | Amydis, Inc.
SAN DIEGO, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Amydis Inc., a leading ocular tracer pharmaceutical company with a broad portfolio of diagnostic drug candidates targeting CNS biomarkers in the eye,...
Amydis_Logo_Horiz_RGB@2x.png
Amydis Awarded NIH Ph2A Grant for Cerebral Amyloid Angiopathy
23 sept. 2019 07h00 HE | Amydis, Inc.
SAN DIEGO, Sept. 23, 2019 (GLOBE NEWSWIRE) -- Amydis, Inc., a privately-held pharmaceutical company developing proprietary drugs to detect, monitor, and screen for amyloid-related diseases,...
Amydis_Logo_Horiz_RGB@2x.png
Optos and Amydis Establish Clinical Alliance to Develop Early Diagnostic Test for Alzheimer’s Disease
24 oct. 2018 07h00 HE | Amydis, Inc.
LOS ANGELES, Oct. 24, 2018 (GLOBE NEWSWIRE) -- Optos Plc, a subsidiary of Nikon Corporation, Japan, and Amydis, Inc. today announced a clinical alliance focused on the development of an eye test by...
IGC Announces Result
IGC Announces Results of Annual Shareholders Meeting
13 nov. 2017 14h22 HE | India Globalization Capital
BETHESDA, Md., Nov. 13, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE American:IGC), announced that during its 2016-2017 Annual Meeting of Shareholders scheduled for, and convened...
IGC-AD1 Targeting Al
IGC-AD1 Targeting Alzheimer’s Disease to be commercialized in early 2018 Through Medical Dispensaries
18 oct. 2017 08h00 HE | India Globalization Capital
BETHESDA, Md., Oct. 18, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides compelling in vitro data compiled from genetically engineered cell lines within an...
IGC Prepares a Liqui
IGC Prepares a Liquid Delivery Formulation of IGC-AD1 for Alzheimer’s Based on Novel In Vitro Data
04 oct. 2017 08h00 HE | India Globalization Capital
BETHESDA, Md., Oct. 04, 2017 (GLOBE NEWSWIRE) -- India Globalization Capital, Inc. (NYSE-MKT:IGC) provides an update on compelling in vitro data compiled from genetically engineered cell lines...